Press releases
GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis
GlaxoSmithKline plc (GSK) today announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis – a condition that involves inflammation of the blood vessels.
GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK
GlaxoSmithKline plc has announced the marketing authorisation of its quadrivalent (four-strain) influenza vaccine in Germany and the UK.
Regulatory update: GlaxoSmithKline receives complete response from FDA for candidate pandemic H5N1 adjuvanted influenza vaccine
GlaxoSmithKline [NYSE:GSK] announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) in response to the Biologics License Application (BLA) for its Pandemic Influenza A Virus Monovalent Adjuvanted candidate vaccine, referred to as Q-Pan H5N1.
GSK publishes 2012 Corporate Responsibility report
Report sets out 23 forward-looking commitments to help measure future performance
$500,000 Endowment Gift from The GlaxoSmithKline Foundation Expands Program to Help Patients with Cancer and their Families at The Children’s Hospital of Philadelphia
Donation Will Enable Patients and Families with Limited Financial Means to Benefit from Cutting-Edge Cancer Research and Treatments at Children’s Hospital
Young scientists challenged by GSK and McLaren to help drive science behind Formula 1™
GSK and the McLaren Group announce new science education initiative to inspire young people into science and engineering careers
Regulatory update – GSK announces regulatory submission for albiglutide in Europe
GlaxoSmithKline plc (GSK) today announced the submission of a Marketing Authorisation Application (MAA) for albiglutide, with the proprietary name EPERZAN, to the European Medicines Agency (EMA).
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
ViiV Healthcare presents 24-week interim results from Phase III SAILING study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI)
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children
Agreement brings the number of voluntary licences granted by ViiV Healthcare to 14.
GSK and Theravance announce FDA acceptance of New Drug Application (NDA) submission in the US for ANORO ELLIPTATM for COPD
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the New Drug Application (NDA) for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD), has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review
